Arrowhead Pharmaceuticals Licenses ARO-PNPLA3 to Madrigal Pharmaceuticals in a ~$1B Deal

Shots:

• Arrowhead has granted Madrigal an exclusive global license to ARO-PNPLA3, a RNAi therapeutic designed to reduce liver expression of PNPLA3 as a potential treatment of metabolic dysfunction-associated steatohepatitis
• As per the deal, Arrowhead will receive $25M upfront & ~$975M in development, regulatory, & sales milestones, with tiered royalties ranging from high-single digits to the mid-teens
• In a P-I trial, ARO-PNPLA3 showed ~46% liver fat reduction at 12wks. in 55 pts with MAFLD carrying the PNPLA3 I148M variant, with effects seen by 6wks. & sustained through ≥24wks.; no benefit was seen in heterozygous pts, while the Japanese P-I study (n=9) supported the findings

Ref: Businesswire  |  Image: Arrowhead & Madrigal  |Press Release

Related News: Arrowhead Pharmaceuticals Receives the CHMP’s Positive Opinion for Redemplo (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com